Dare Bioscience | Investor Presentation Deck

Dare Bioscience | Investor Presentation Deck | 26 slides

Daré Bioscience · 2023-08

arc beats above · slides in the middle · loops below · scroll → 1 LOOPS

Deck intelligence map

coverage by narrative range · generated from this deck JSON

Narrative range 5 total

Metadata

Components

Metrics

Tools

Frameworks

Beats

Loops

Problem 1 slides 100% 1/1 slides 100% 1/1 slides · 5 hits

— 0/1 slides

100% 1/1 slides 100% 1/1 slides 100% 1/1 slides · 2 hits 100% 1/1 slides Solution 3 slides 100% 3/3 slides 100% 3/3 slides · 12 hits

— 0/3 slides

33.3% 1/3 slides 33.3% 1/3 slides 100% 3/3 slides · 4 hits 66.7% 2/3 slides Market Size 1 slides 100% 1/1 slides 100% 1/1 slides · 6 hits

— 0/1 slides

100% 1/1 slides 100% 1/1 slides

— 0/1 slides

Slide inventory

every slide · same image gating as the playbook

The slide uses a linguistic play on the company name to establish brand identity.inspire_vision

Open slide detail

Dense legal text page typical of investor decks; Dare Bio logo top-left, page number '2' bottom-right.front_matter

Open slide detail

The slide uses a two-column layout to contrast company strengths with market opportunity.summarize

Open slide detail

The slide uses a structured list format to categorize assets under Contraception, Vaginal Health, Reproductive Health/Menopause/Sexual Health, and Fertility.present_solution

Open slide detail

The slide uses a Gantt-style chart to map product development stages against clinical phases.plan_implementation

Open slide detail

The slide uses a Gantt-style layout to track drug development progress.plan_implementation

Open slide detail

present_solution

Open slide detailBeat · Solution

The slide uses a comparison to erectile dysfunction to frame the market opportunity.frame_problem

Open slide detailBeat · ProblemLoop · Cost Of Inaction

The slide uses a yellow underline to emphasize the lack of FDA-approved treatments.present_solution

Open slide detailBeat · SolutionLoop · Cost Of Inaction

The slide outlines the methodology and endpoints of a clinical trial.analyze_data

Open slide detailLoop · Cost Of Inaction

The slide highlights clinical trial outcomes and regulatory next steps.show_traction

Open slide detailLoop · Cost Of Inaction

The slide serves as a transition or focus slide for the company's lead product.present_solution

Open slide detail

Includes specific revenue data for Mirena, Lo Loestrin, and NuvaRing as market benchmarks.size_opportunity

Open slide detailBeat · Market Size

The slide uses a vertical axis to represent effectiveness, positioning the company's proposed solution between existing barrier methods and the Copper IUD.compare_peers

Open slide detail

Includes a quote from a Bayer executive regarding the collaboration.cite_precedent

Open slide detail

Includes clinical trial data table and regulatory roadmap steps.analyze_data

Open slide detail

Includes a yellow highlight on the $310 million milestone figure.show_traction

Open slide detail

This slide serves as a formal product introduction/disclaimer page.other

Open slide detail

The slide highlights a key partnership and associated financial milestones.show_traction

Open slide detail

Includes regulatory status and go-to-market synergy with existing Organon product NEXPLANON.present_solution

Open slide detail

Standard pharmaceutical safety disclosure slide.other

transition

plan_implementation

transition

The slide uses a bulleted list format to outline specific program milestones for five different assets.plan_implementation

Open slide detail

The slide uses a dual-image layout to emphasize empowerment and collaboration.inspire_vision

Open slide detail